The potential of these new disease-modifying treatments represents a defining moment for Alzheimer’s disease. However, currently, health care systems across the UK are not ready to deliver breakthrough treatments if they become available. Over a third of people living with dementia in the UK don't have a diagnosis. This means they can’t access the vital care, support and treatment a diagnosis can bring, including both existing symptomactic treatments and the disease-modifying treatments of the future, if approved.
For more details on our calls, visit our webpage here.